About this Journal Submit a Manuscript Table of Contents

Strategies of Enhancement for Anticancer Immunotherapies

Call for Papers

Immunotherapy for cancer has undergone a recent renaissance after the FDA approval of sipuleucel-T for castration-recurrent minimally symptomatic prostate cancer. Recent data have shown exciting results for immune checkpoint mechanisms, such as CTLA-4 and PD-1 pathways. Cellular vaccine strategies are being investigated in a variety of diseases. In particular, dendritic cell-based approaches are of great interest. In this context, a number of concepts are under investigation, such as what is the most cost efficient and immunologically effective method of DC vaccine generation? One aspect of immunotherapy that is of significant interest is the question of target antigens, and a variety of approaches are under investigation to improve the expression of antigens on tumor cells. The past decade has enhanced our understanding of immunosuppressive cell populations, such as regulatory T cells or myeloid-derived suppressor cells. Their role in the context of immunotherapeutic approaches has not been well characterized. Recent data have shown that cancer patients who respond to immunotherapy may demonstrate a distinct genomic profile in their immune effector cells. This may facilitate the enrichment of immunotherapy trials. The field of anticancer therapy has been revolutionized by the advent of targeted pathway agents, such as tyrosine kinase inhibitors. Recent data demonstrate that these agents may have immune modulatory effects.

We invite investigators to contribute to original research articles as well as review articles that will stimulate the continuing efforts on the improvement of immunotherapeutic approaches forcancer. We are particularly interested in articles describing “outside the box” immunotherapeutic approaches as well as translational animal model. Potential topics include, but are not limited to:

  • Recent early clinical trials utilizing immunotherapeutic approaches
  • Immune monitoring
  • Genomic analyses of immunotherapeutic approaches
  • Combination therapies (radiation, TKIs, and immune checkpoint inhibitors)
  • Novel approaches to target antigens

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/urology/cancim/ according to the following timetable:

Manuscript DueFriday, 14 February 2014
First Round of ReviewsFriday, 9 May 2014
Publication DateFriday, 4 July 2014

Lead Guest Editor

Guest Editors